Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis

Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie Gertz, David M Dingli, Dragan Jevremovic, William G. Morice, Prashant Kapoor, Taxiarchis Kourelis, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, Nelson Leung, Ronald S. Go, Yi Lin, Stephen J Russell, John A. Lust, Steven R. Zeldenrust, Rahma Warsame, Yi L. HwaMiriam Hobbs, Amie Fonder, Robert A. Kyle, S Vincent Rajkumar, Shaji K Kumar, Wilson Gonsalves

Research output: Contribution to journalArticle

6 Scopus citations


We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. Of the 154 patients who underwent MFC, cPCs were detected in 42% (n = 65) patients. Median number of cPCs was 81 per 150,000 events (range: 6-17,844). High bone marrow plasma cell percentage was an independent predictor of presence of cPCs. Presence of cPCs at diagnosis was associated with inferior overall survival (OS) (90 vs. 98 months, p = 0.003) and inferior progression free survival (PFS) (31 vs. 52 months, p = 0.02). Estimated 1, 2 and 5 year OS in the two groups was: 74, 64 and 57 and 89, 87, and 80%, respectively. Estimated PFS at 1, 2, and 5 years was: 69, 56, and 23% and 80, 74, and 37%, respectively. Furthermore, the presence of cPCs at diagnosis was an independent adverse predictor of OS in multivariable analysis. Achieving a very-good partial response, or better, was able to overcome the adverse impact of cPCs at diagnosis. Patients with cPCs at diagnosis may warrant closer monitoring post-treatment, especially if they do not achieve a deep hematologic response.

Original languageEnglish (US)
Pages (from-to)1421-1426
Number of pages6
Issue number6
StatePublished - Jun 1 2018


ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this